CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced two presentations of data for two new potential applications in oncology of its novel agonists of Toll-like receptor 9 (TLR9) at the Annual Meeting of the American Association for Cancer Research (AACR) being held in Los Angeles, CA, April 14-18, 2007. The first presentation covered a preclinical study in which Idera’s lead oncology candidate, IMO-2055, in combination with the multikinase inhibitor sorafenib, showed enhanced antitumor activity compared to either agent alone in a mouse xenograft model. The second presentation covered a preclinical study in which an analog of IMO-2055 optimized for mice was administered by the intranasal route and showed potent antitumor activity in mouse models of lung metastases of colon carcinoma and melanoma.
